Pierrick Coupé, Boris Mansencal, Floréal Morandat, Sergio Morell-Ortega, Nicolas Villain, Jose V Manjón, Vincent Planche
{"title":"petBrain：利用PET和MRI对淀粉样蛋白、Tau缠结和神经变性进行量化的新途径。","authors":"Pierrick Coupé, Boris Mansencal, Floréal Morandat, Sergio Morell-Ortega, Nicolas Villain, Jose V Manjón, Vincent Planche","doi":"10.1186/s13195-025-01839-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Quantification of amyloid plaques (A), neurofibrillary tangles (T<sub>2</sub>), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration.</p><p><strong>Methods: </strong>We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T<sub>2</sub>, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge.</p><p><strong>Results: </strong>petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T<sub>2</sub>, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T<sub>2</sub>/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance.</p><p><strong>Discussion: </strong>petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"17 1","pages":"209"},"PeriodicalIF":7.6000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482854/pdf/","citationCount":"0","resultStr":"{\"title\":\"petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI.\",\"authors\":\"Pierrick Coupé, Boris Mansencal, Floréal Morandat, Sergio Morell-Ortega, Nicolas Villain, Jose V Manjón, Vincent Planche\",\"doi\":\"10.1186/s13195-025-01839-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Quantification of amyloid plaques (A), neurofibrillary tangles (T<sub>2</sub>), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration.</p><p><strong>Methods: </strong>We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T<sub>2</sub>, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge.</p><p><strong>Results: </strong>petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T<sub>2</sub>, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T<sub>2</sub>/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance.</p><p><strong>Discussion: </strong>petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.</p>\",\"PeriodicalId\":7516,\"journal\":{\"name\":\"Alzheimer's Research & Therapy\",\"volume\":\"17 1\",\"pages\":\"209\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482854/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's Research & Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13195-025-01839-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-025-01839-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI.
Introduction: Quantification of amyloid plaques (A), neurofibrillary tangles (T2), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration.
Methods: We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T2, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge.
Results: petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T2, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T2/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance.
Discussion: petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.
期刊介绍：
Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
